A controlled trial with vasopressin analogue (DGAVP) on cognitive recovery immediately after head trauma.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 8423870.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent evidence suggests that the vasopressin analogue desglycinamide-arginine8-vasopressin (DGAVP) might specifically benefit mild brain trauma patients. We investigated the effect of intranasal DGAVP treatment in 32 patients who had sustained a mild head injury for 3 months in a double-blind, placebo-controlled, matched-pairs study. DGAVP did not have a positive effect on cognitive recovery in this group of mildly affected patients.
Medical subject headings
- Arginine Vasopressin
- Cognition Disorders
- Craniocerebral Trauma